Use of digital twins in a Phase 2a trial to predict disease-progression of participants with mild-to-moderate Alzheimer's Disease supports early signals of efficacy

"Digital twins offer a new lens for interpreting biomarker trends over time, especially in early-stage trials where every data point matters." Gerard Griffioen, Ph.D., CSO, reMYND. Presented at AD/PD 2025, Boston, MA.